Cetuximab for the first-line treatment of metastatic colorectal cancer This guidance was developed using the single technology appraisal process NICE technology appraisal guidance 176 Cetuximab for the first-line treatment of metastatic colorectal cancer
You can download the following documents from www.nice.org.uk/TA176 • The NICE guidance (this document).
• A quick reference guide -the recommendations.
• 'Understanding NICE guidance' -a summary for patients and carers.
• Details of all the evidence that was looked at and other background information.
For printed copies of the quick reference guide or 'Understanding NICE guidance', phone NICE publications on 0845 003 7783 or email publications@nice.org.uk and quote:
• N1979 (quick reference guide) • N1980 ('Understanding NICE guidance').
This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties. cancer only when all of the following criteria are met:
• The primary colorectal tumour has been resected or is potentially operable.
• The metastatic disease is confined to the liver and is unresectable.
• The patient is fit enough to undergo surgery to resect the primary colorectal tumour and to undergo liver surgery if the metastases become resectable after treatment with cetuximab.
• The manufacturer rebates 16% of the amount of cetuximab used on a per patient basis.
Cetuximab in combination with 5-FU, folinic acid and irinotecan
(FOLFIRI), within its licensed indication, is recommended for the first-line treatment of metastatic colorectal cancer only when all of the following criteria are met:
• The patient is unable to tolerate or has contraindications to oxaliplatin.
1.3
Patients who meet the criteria in 1.1 and 1.2 should receive treatment with cetuximab for no more than 16 weeks. At 16 weeks, treatment with cetuximab should stop and the patient should be assessed for resection of liver metastases.
1.4
People with metastatic colorectal cancer with metastatic disease confined to the liver who receive cetuximab should have their treatment managed only by multidisciplinary teams that involve highly specialised liver surgical services.
The technology
2.1 Cetuximab (Erbitux, Merck Serono) is a recombinant monoclonal antibody that blocks the human epidermal growth factor receptor (EGFR) and therefore inhibits the proliferation of cells that depend on EGFR activation for growth. Cetuximab is indicated for the treatment of patients with EGFR-expressing, Kirsten rat sarcoma (KRAS) wild-type metastatic colorectal cancer:
• in combination with chemotherapy
• as a single agent in patients who have failed oxaliplatin-and irinotecan-based therapy and who are intolerant to irinotecan.
2.2
One common adverse effect of cetuximab treatment is the development of skin reactions, which occur in more than 80% of patients and mainly present as an acne-like rash or, less frequently, as pruritus, dry skin, desquamation, hypertrichosis or nail disorders (for example, paronychia). The majority of skin reactions develop within the first 3 weeks of treatment. The summary of product characteristics (SPC) notes that if a patient experiences a grade 3 or 4 skin reaction, cetuximab treatment must be stopped, with treatment being resumed only if the reaction resolves to grade 2.
Other common adverse effects of cetuximab include mild or moderate infusion-related reactions such as fever, chills, nausea, vomiting, headache, dizziness or dyspnoea that occur soon after the first cetuximab infusion. For full details of adverse effects and contraindications, see the SPC.
2.3
The acquisition cost of cetuximab is £159.02 for a 5-mg/ml, 20-ml 
Clinical effectiveness

3.1
In the submission, the manufacturer compared a regimen of cetuximab in combination with FOLFIRI with the FOLFIRI chemotherapy regimen alone, and a regimen of cetuximab in combination with FOLFOX with the FOLFOX chemotherapy regimen alone.
3.2
The main evidence on the efficacy of cetuximab in the manufacturer's submission was derived from two randomised controlled trials:
• CRYSTAL (n = 1198), a phase III, multicentre, open-label randomised controlled trial, which compared cetuximab in combination with FOLFIRI with FOLFIRI alone, and examined progression-free survival as the primary outcome.
• OPUS (n = 336), a phase II, multicentre, open-label randomised controlled trial, which compared cetuximab in combination with FOLFOX with FOLFOX alone, and examined response rate as the primary outcome.
The participants in both trials were patients with previously untreated metastatic colorectal cancer with non-resectable metastases and an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2 at study entry. The planned treatment duration in both trials was until demonstration of progressive disease by computed tomography (CT) or magnetic resonance imaging (MRI), withdrawal of consent, or occurrence of unacceptable adverse events (CRYSTAL only) or toxicity (OPUS only).
3.3
In the submission, the manufacturer presented data for the full analysis set (people with KRAS wild-type metastatic colorectal cancer and KRAS mutations) for both trials. However, the main data in the submission focused on the post hoc analysis of the KRAS wild-type subgroup (n = 348 for the CRYSTAL trial; n = 134 for the OPUS trial), which was requested by the regulatory agencies and reflects the licensed indication.
3.4
In response to ACD consultation, the manufacturer submitted updated overall survival data from the CRYSTAL trial (described in sections 3.5 and 3.7) and additional clinical evidence on the rates of liver resection (described in sections 3.12 and 3.13).
3.5
The results of the full analysis set for the CRYSTAL study showed an improved progression-free survival for cetuximab in combination (n = 3) for FOLFOX alone (statistical significance was not reported for this outcome).
3.9
The CRYSTAL trial also reported results for people in the KRAS wild-type subgroup who had metastatic disease confined to the liver (n = 67). The addition of cetuximab to FOLFIRI increased the median progression-free survival from 9.5 months to 14.6 months.
However, this difference was not statistically significant (HR = 0.724, p = 0.437). Cetuximab in combination with FOLFIRI was associated with a statistically significant increase in response rate compared with FOLFIRI alone (77.1%, 95% CI 59.9 to 89.6 versus 50.0%, 95% CI 31.9 to 68.1, p = 0.0246).
3.10 Quality of life was assessed in the CRYSTAL study using the QLQ-C30 and the EuroQol (EQ-5D) questionnaires. In the KRAS wild-type subgroup, some measures of the QLQ-C30 showed statistically significant differences between the two treatment groups in favour of the FOLFIRI-only group (mean change from baseline to worst physical functioning score, and dyspnoea scores).
Only 37 patients completed evaluable baseline EQ-5D 
3.13
The results of the interim analysis of the data from the CELIM trial showed that the liver resection rate for cetuximab in combination with FOLFIRI (n = 53) was 43% compared with 40% for cetuximab in combination with FOLFOX (n = 52). For all patients in the trial (n = 105) the liver resection rate was 42%, and for the KRAS wildtype subgroup (n = 67) it was 43%. For those patients who had technically non-resectable liver metastases at baseline (n = 57) the liver resection rate was 40%.
3.14 The ERG considered that there were a number of limitations with the evidence in the manufacturer's submission. It noted that the KRAS wild-type analysis was carried out post hoc and was likely to have been underpowered. It also noted that the differences in progression-free survival of 1.2 months and 0.5 months for the CRYSTAL and OPUS trials' KRAS wild-type populations, respectively, were statistically significant in favour of cetuximab but not clinically meaningful. The ERG was also uncertain of the accuracy of the KRAS test in clinical practice.
3.15
The ERG identified a number of limitations with the evidence from the CELIM study. It was concerned that the study was not a randomised assessment of cetuximab compared with no cetuximab. Therefore the ERG was uncertain whether the higher rates of resection were because of cetuximab treatment or other factors in the study such as those associated with patient care, surgical practice and patient characteristics. The ERG noted that inclusion criteria for the study specified patients with non-resectable liver metastases, with 55% of patients having technically nonresectable metastases at baseline and 45% having five or more liver metastases. In addition, the ERG commented that the sample size in the trial was relatively small, with approximately 55 patients in each arm.
Cost effectiveness
3.16
The manufacturer developed a semi-Markov model to simulate the disease progression and survival of a cohort of patients with EGFRexpressing, KRAS wild-type metastatic colorectal cancer throughout first and subsequent lines of treatment (second-and third-line) including longer-term survival after successful curative surgery. The model had a cycle length of 1 week and estimated costs and benefits over a lifetime horizon (approximately 23 years).
3.17
The analysis looked at two treatment strategies: cetuximab in combination with FOLFIRI compared with FOLFIRI alone, and cetuximab in combination with FOLFOX compared with FOLFOX alone. The economic evaluation focused on a population with the following characteristics:
• Good performance status (the majority of KRAS wild-type patients in the CRYSTAL and OPUS trials [96% and 90%, respectively] had an ECOG performance status of 0 or 1, so this was reflected in the modelled cohort).
• Suitable for irinotecan-or oxaliplatin-containing chemotherapy.
• Metastatic disease confined to the liver, excluding people whose liver metastases were resectable at presentation.
3.18
The analysis assessed the impact of cetuximab in combination with The correlation observed between response rates and resection rates was used to model resection rates in the base case and different scenarios in the model. The value for the failure rate of liver resection used in the model was 27.8%, which was taken from the full analysis set from the CRYSTAL trial. This rate was applied to all arms in the model.
3.21
The cost data were taken from the BNF edition 55 (2008) 
4.6
The Committee reviewed the additional clinical data submitted by the manufacturer on the liver resection rates. It noted that the CELIM trial was not a randomised assessment of cetuximab in combination with chemotherapy compared with chemotherapy alone, had a relatively small sample size and had not been peerreviewed. The Committee was initially concerned that only 55% of patients were described as having technically non-resectable liver metastases at baseline; however, the Committee then noted that the remaining 45% had at least five or more liver metastases at baseline, and were therefore also non-resectable. It noted that the subgroup analysis for these two groups of patients indicated a liver resection rate of 40% and 44% respectively, but that this subgroup analysis was for all patients and not just those with KRAS wild-type metastatic colorectal cancer. The Committee heard from the clinical specialists that the 43% liver resection rate for patients with KRAS wild-type metastatic colorectal cancer who were treated with cetuximab was an encouraging result, but it also noted that this was higher than the 30-35% rate originally considered likely by the clinical specialists (see section 4.5). The Committee was concerned that the 22% liver resection rate for FOLFOX was taken from an older study (GERCOR, Tournigand et al. 2004 ), but noted that the clinical specialists suggested that a liver resection rate of approximately 20% for FOLFOX was appropriate for current UK clinical practice (see section 4.5).
4.7
The Committee discussed the failure rate of liver resection. It noted that the 27.8% failure rate used in the original analysis appeared high for current practice. The Committee heard from the clinical specialists that a 5% failure rate of liver resection was a more appropriate reflection of current practice in UK specialist centres.
The Committee agreed that this low rate reflected improvements in preoperative assessment and surgical technique and was appropriate to be used in the model.
4.8
The Committee discussed the adverse effects related to cetuximab.
The clinical specialists advised the Committee that cetuximab is associated with an increase in an acne-like rash affecting a person's upper trunk, gastrointestinal adverse effects such as diarrhoea, and fatigue. The clinical specialists and patient experts explained that the acne-like rash may be indicative of response to cetuximab treatment and would not usually cause admission to hospital. Therefore, it is often interpreted by people as a positive effect because it suggests that the drug is working, outweighing any negative effects of the rash.
4.9
The Committee considered the results of the economic analysis submitted by the manufacturer. The Committee noted that the manufacturer had not provided an economic analysis that included the entire population for which cetuximab is licensed. The economic model focused on a subgroup of patients with a good performance status and metastatic disease confined to the liver.
The Committee was persuaded that, in this group of patients, the aim of treatment with cetuximab was to reduce the size of metastases so they were resectable. Therefore the most 
4.10
The Committee was aware that in the manufacturer's new 16-week analysis (incorporating a 5% failure rate of liver resection, 43% liver resection rate, lifetime horizon and the patient access scheme), the ICER for cetuximab in combination with FOLFOX compared with FOLFOX alone was £18,700 per QALY gained (see section 3.31).
The Committee was concerned about the limited methodology used for estimating the resection rates in the model, in that single arms from two separate studies were used to provide the data for the two groups in the model; the CELIM study for cetuximab in combination with FOLFOX and the GERCOR study for FOLFOX alone. The
Committee considered that exploration of the different populations and evaluation of possible selection biases between the trials had not been done to a satisfactory level. Therefore, the Committee expressed caution about the results produced by the new analysis using a 43% resection rate for cetuximab in combination with FOLFOX, as the relative difference in resection rates was assumed from unrelated studies without any adjustments. It noted the sensitivity analysis requested from the manufacturer, which used resection rates of 35% and 30% for cetuximab in combination with FOLFOX (assuming a 22% resection rate for FOLFOX alone), resulted in ICERs of £24,600 and £31,000 per QALY gained, respectively. The Committee agreed that a 35% liver resection rate for cetuximab in combination with FOLFOX compared with the 22%
for FOLFOX alone more closely reflected the 10-15% relative difference in resection rates for these two comparators considered to be realistic by the clinical specialists and was a more appropriate value to use in the economic analysis.
4.11
The Committee discussed the cost of liver resection included in the economic analysis. It noted that the manufacturer had originally used a weighted average of a range of healthcare resource groups for all liver procedures giving an average cost of £2300 for liver resection surgery, and that this only occurred once in the model.
The Committee considered that this cost could be low compared with current UK clinical practice because a proportion of patients may undergo more than one operation to achieve complete resection of metastases. In addition, the Committee heard from the clinical specialists that liver resection costs £7000 per case. The • The primary colorectal tumour has been resected or is potentially operable.
• The duration of treatment with cetuximab is restricted to 16 weeks. Committee therefore concluded that cetuximab in combination with FOLFIRI should be recommended for first-line treatment of metastatic colorectal cancer when the following criteria are met:
• The duration of treatment with cetuximab is restricted to 16 weeks.
4.15
The Committee was aware that, in current UK clinical practice, the treatment of patients with metastatic colorectal cancer receiving potentially curative resection of metastases confined to the liver is managed by multidisciplinary teams involving highly specialised liver surgical services. The Committee concluded that current practice for this population was the most appropriate approach, and that patients should continue to be managed in this way. • Costing report and costing template to estimate the savings and costs associated with implementation.
Implementation
• Audit support for monitoring local practice.
6
Recommendations for further research • Bevacizumab in combination with oxaliplatin and either 5-FU or capecitabine for the treatment of metastatic colorectal cancer. NICE technology appraisal (publication date to be confirmed).
• Diagnosis and management of colorectal cancer. NICE clinical guideline (publication expected July 2011).
Review of guidance
8.1
The review date for a technology appraisal refers to the month and year in which the Guidance Executive will consider whether the technology should be reviewed. This decision will be taken in the light of information gathered by the Institute, and in consultation with consultees and commentators.
8.2
The guidance on this technology will be considered for review in 
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Each technology appraisal is assigned to a team consisting of one or more health technology analysts (who act as technical leads for the appraisal), a technical adviser and a project manager.
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